PAVmed vs Profusa
PAVM and PFSA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PAVM and PFSA compare
PAVmed is the larger company, worth 262 times as much as Profusa ($12.1M against $46.0K).
PAVmed scores higher on the StockData Score (6 against 0 for Profusa), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PAVM | PFSA |
|---|---|---|
| Size and price | ||
| Market cap | $12.1M | $46.0K |
| Share price | $1.51 | $0.348 |
| Change, 1 year | −84.3% | −100.0% |
| Change, 5 years | −99.9% | – |
| Beta (5Y) | 1.47 | 3.29 |
| Employees | 3 | – |
| StockData Score | ||
| Total score | 6 (better) | 0 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 4 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 108× | – |
| P/B | 0.3× | – |
| FCF yield | −64.5% | – |
| Growth | ||
| Revenue growth (TTM) | −89.0% | – |
| Net income growth (TTM) | −117% | – |
| Profitability | ||
| Gross margin | −221% | – |
| Operating margin | −23843% | – |
| Net margin | −10795% | – |
| FCF margin | −6948% | – |
| Return on equity | −33.3% | – |
| Return on invested capital | −65.1% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −3338.0× | −136.6× (better) |
| Current ratio | 1.19 (better) | 0.03 |
| Altman Z-score | −11.03 (better) | −364.70 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 11.7% | 25.3% |
| Held by insiders | 23.5% | – |
| Insider net buying, 12 months | – | −$116K |
| Short interest, % of float | 0.21% | – |
Go deeper
- PAVM stock overview
- PAVM income statement
- PAVM valuation and score
- PFSA stock overview
- PFSA income statement
- PFSA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.